Effect of gemfibrozil on the pharmacokinetics of pioglitazone

European Journal of Clinical Pharmacology

Volumn 61, Issue 11, 2005, Pages 831-836

  Deng, Li Jing ^a,b   Wang, Feng ^a   Li, Huan De ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Gemfibrozil; Inhibit; Pharmacokinetic; Pioglitazone

Indexed keywords

CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DRUG METABOLITE; GEMFIBROZIL; NUO HENG; PIOGLITAZONE; PLACEBO; RUI TONG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; INHIBITION KINETICS; MALE; METHODOLOGY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; VOLUNTEER;

ADULT; ANTILIPEMIC AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; GEMFIBROZIL; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; THIAZOLIDINEDIONES;

EID: 28344441475     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0042-6     Document Type: Article

References (15)

1. Füchtenbusch M, Standl E, Schatz H (2000) Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 108:151-163
2. Kiyota Y, Kondo T, Maeshiba Y (1997) Studies on the metabolism of the new antidiabetic agent pioglitazone. Identification of metabolites in rats and dogs. Arzneimittelforschung 47:22-28
3. Tanis SP, Parker TT (1996) Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent Pioglitazone. J Med Chem 39:5053-5063
4. Hiraga K (1997) Clinical phase 1 study of AD-4833: single-dose and repeated-dose studies. Jpn J Clin Exp Med 74:1184-1201
5. Niemi M, Backman JT, Granfors M, Laitila J (2003) Gemfibrozil considerably increases the plasma concentration of rosiglitazone. Diabetologia 46:1319-1323
6. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691
7. Deng LJ, Wang F, Xie HZ, Li HD (2005) Simultaneous determination of pioglitazone and its two active metabolites in human plasma by HPLC-MS. Chin Pharm J 40:616-620
8. Diletti E, Hauschke D, Steinijans VW (1991) Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29:1-8
9. Steinijans VW, Hartmann M, Huber R, Radtke HW (1991) Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 29:323-328
10. Eckland DA, Danhof M (2002) Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol 108:s234-s242
11. Sahi J, Black CB, Hamilton GA (2003) Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 31:439-446
12. Wen X, Wang JS, Backman JT, Kivistö KT, Neuvonen PJ (2001) Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 29:1359-1361
13. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ (2003) Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46:347-351
14. Prueksaritanont T, Richards KM, Qiu Y (2005) Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res 22:71-78
15. Niemi M, Pertti J, Kari T (2001) Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 70:439-451